Immunic Analyst Price Targets - Benzinga

Immunic Inc

IMUXNASDAQ

Trade with Public

Trade with Public

$7.95

-0.24-2.93%

마지막 업데이트: Oct 12, 4:25 PM

$7.97

-0.22-2.69%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Immunic Analyst Price Targets - Benzinga

Immunic Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immunic (IMUX).

Price Target Range — 10 Quarters

Analyst Consensus — 12 Analysts

11Buy

1Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$60Upside to Avg. PT+651.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	Wedbush	Martin Fan	Maintained	Outperform	$45
Sep 10, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$22
Aug 17, 2026	Wedbush	Martin Fan	Initiate	Outperform	$45
May 22, 2026	B. Riley Securities	William Woods	PT Cut	Buy	$40→$27
Apr 30, 2026	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$5→$22
Apr 17, 2026	Stifel	Paul Matteis	Initiate	Buy	$3
Apr 15, 2026	D. Boral Capital	Jason Kolbert	Downgrade	Buy→Hold	—
Mar 24, 2026	Guggenheim	Yatin Suneja	Initiate	Buy	$7
Mar 2, 2026	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$8→$5
Feb 13, 2026	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$8→$4
Feb 9, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$8
Jan 7, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$8
Nov 14, 2025	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$10→$8
Nov 13, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$10→$8
Sep 29, 2025	Chardan Capital	Rudy Li	Initiate	Buy	$3
Sep 26, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$10
Sep 25, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Aug 8, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Jun 25, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Jun 5, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Immunic, Maintains $45 Price Target

Wedbush analyst Martin Fan reiterates Immunic (NASDAQ:IMUX) with a Outperform and maintains $45 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $22 price target.

Benzinga Newsdesk

PRO
Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45

Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27

B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $27.

Benzinga Newsdesk

Amazon To Rally More Than 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Immunic, Raises Price Target to $22

HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and raises the price target from $5 to $22.

Benzinga Newsdesk